AstraZeneca rebuffs Pfizer approach, report claims
This article was originally published in Scrip
Executive Summary
US big pharma company Pfizer has approached its UK rival AstraZeneca with a £60bn takeover offer, reports The Sunday Times (20 April). AstraZeneca allegedly rebuffed the advance and talks have been discontinued. If such an offer was indeed made, it would equate to roughly £48 per AstraZeneca share, a premium of more than 25% above its last close.
You may also be interested in...
AstraZeneca CEO Says Post-Crestor Future On Track As Pipeline Builds
AstraZeneca's first-half results presentation highlighted its growing early pipeline, notably in oncology, but also the increasing pain of generic erosion on its Crestor sales – underlining again the importance new drugs will play in the group's turnaround strategy.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.